Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.

Lewis, J P; Yerges-Armstrong, L M; Ellero-Simatos, S; Georgiades, A; Kaddurah-Daouk, R; Hankemeier, T

Lewis, J P; Yerges-Armstrong, L M; Ellero-Simatos, S; Georgiades, A; Kaddurah-Daouk, R; Hankemeier, T.

Affiliation

Lewis JP; Division of Endocrinology, Diabetes, and Nutrition and Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Clin Pharmacol Ther ; 94(5): 570-3, 2013 Nov.

Article in En | MEDLINE | ID: mdl-23892404

Subject(s)

Metabolomics/methods; Pharmacogenetics/methods; Platelet Aggregation Inhibitors/pharmacology; Aspirin/metabolism; Aspirin/pharmacology; Cardiovascular Diseases/drug therapy; Cardiovascular Diseases/metabolism; Humans; Platelet Aggregation/drug effects; Platelet Aggregation/genetics; Platelet Aggregation Inhibitors/metabolism

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmacogenetics / Platelet Aggregation Inhibitors / Metabolomics Limits: Humans Language: En Journal: Clin Pharmacol Ther Year: 2013 Document type: Article

Fulltext

XML

PubMed Links

Search on Google